Key result
Salvianolate linked to ~85% lower DVT risk versus enoxaparin after gastrointestinal surgery.
Why the study?
The comparative efficacy and safety of salvianolate versus enoxaparin for preventing perioperative deep vein thrombosis in gastrointestinal surgery were unclear.
Does salvianolate prevent perioperative deep venous thrombosis better than enoxaparin in patients undergoing gastrointestinal surgery?
Cohort (n=119)
Does salvianolate prevent perioperative deep venous thrombosis better than enoxaparin in patients undergoing gastrointestinal surgery?
Salvianolate may be more effective than enoxaparin in preventing perioperative deep vein thrombosis in patients undergoing gastrointestinal surgery.
Answers are grounded in this paper and cite their sources.
Salvianolate merits evaluation for perioperative DVT prevention in GI surgery; hypothesis-generating and should not yet change practice.
OBJECTIVE: In this study, the efficacy and safety of salvianolate were compared with enoxaparin in the prevention of perioperative deep vein thrombosis in gastrointestinal surgery. METHODS: From October 2017 to September 2019, 563 patients who underwent gastrointestinal surgery were collected. Based on the inclusion and exclusion criteria, 119 patients were divided into two groups: enoxaparin group (n = 65) and salvianolate group (n = 54). Comparisons were made regarding the outcomes: prothrombin time (PT), prothrombin activity (PTA), international normalized ratio (INR), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), D-dimer level (D-D), platelet count (PLT), hematokrit (HCT), and incidence of deep vein thrombosis (DVT). RESULTS: The main outcomes showed no significance between enoxaparin group and salvianolate group (p > .05). The incidence of DVT in salvianolate group was 1.85%, significantly lower than that in enoxaparin group (12.3%) (p < .05). No serious adverse reactions occurred in the two groups during treatment. CONCLUSION: Compared with enoxaparin, salvianolate has an advantage in the prevention of perioperative thrombosis in gastrointestinal surgery with a lower incidence of DVT.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) conducted a cohort in gastrointestinal surgery (n=119). salvianolate vs. enoxaparin was evaluated on incidence of deep vein thrombosis (DVT) (p=< .05). Salvianolate was associated with a significantly lower incidence of deep vein thrombosis compared to enoxaparin in patients undergoing gastrointestinal surgery (1.85% vs 12.3%; p < 0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: